GSK-923295: A Potent CENP-E Inhibitor for Mitotic Checkpoint Research

Executive Summary: GSK-923295 is a nanomolar inhibitor of the mitotic kinesin motor protein CENP-E, with a Ki of 3.2 nM under in vitro conditions (APExBIO). CENP-E is essential for accurate chromosome alignment during metaphase, integrating mitotic checkpoint signals (Walsh et al., 2026). Inhibition with GSK-923295 arrests the cell cycle in mitosis, mimicking CENP-E knockdown phenotypes. In vivo, GSK-923295 induces dose-dependent tumor regression and apoptosis in mouse xenograft models. The compound is supplied by APExBIO for research use and has defined solubility and storage characteristics.

Biological Rationale

The accurate segregation of chromosomes during mitosis is fundamental for genomic stability. The mitotic spindle, composed of microtubules, attaches to chromosomes via kinetochores that localize to the centromere region (Walsh et al., 2026). CENP-E (centromere-associated protein E) is a kinesin motor protein required for chromosome congression and alignment at the metaphase plate (GSK-923295: Mechanistic Insights). Loss or inhibition of CENP-E disrupts this alignment, leading to mitotic errors, aneuploidy, and potential tumorigenesis. Targeting the mitotic checkpoint pathway, including CENP-E, represents a rational strategy for anti-cancer drug development.

Mechanism of Action of GSK-923295

GSK-923295 is a small-molecule inhibitor that binds to the ATPase domain of CENP-E with high affinity (Ki = 3.2 nM). It suppresses CENP-E's microtubule-stimulated ATPase activity by stabilizing the ATP-bound form and retarding the release of ADP and inorganic phosphate (APExBIO). This leads to persistent mitotic arrest due to failed chromosome alignment and activation of the spindle assembly checkpoint. Morphological outcomes of GSK-923295 exposure closely resemble those of RNAi-mediated CENP-E knockdown. The compound does not directly affect other kinesins or microtubule dynamics at comparable concentrations, supporting high specificity.

Evidence & Benchmarks

• GSK-923295 inhibits the ATPase activity of CENP-E with a Ki of 3.2 nM in enzymatic assays (APExBIO).
• In vitro, it suppresses proliferation of 237 human tumor cell lines with an average GI₅₀ of 253 nM and a median GI₅₀ of 32 nM, measured in standard cell viability assays (APExBIO).
• In mouse Colo205 colon cancer xenograft models, intraperitoneal administration at 125 mg/kg produced dose-dependent tumor regression and increased apoptosis rates (APExBIO).
• Mitotic arrest and phenotypic changes induced by GSK-923295 are consistent with those observed in CENP-E RNAi knockdown models (GSK-923295: Mechanistic Insights).
• CTCF depletion does not prevent CENP-E localization at the kinetochore, but CENP-E inhibition phenocopies certain chromosome alignment defects, linking these pathways mechanistically (Walsh et al., 2026).

Applications, Limits & Misconceptions

GSK-923295 is widely adopted in cancer research to study mechanisms of mitotic checkpoint signaling, chromosome alignment, and cell cycle regulation. It is suitable for use in cellular proliferation, cytotoxicity, and apoptosis assays, as well as in vivo tumor xenograft models. The compound’s specificity for CENP-E enables precise dissection of mitotic spindle checkpoint pathways.

For a comprehensive overview on integrating GSK-923295 into translational research and advanced cell cycle studies, see GSK-923295 and the New Frontier in Mitotic Kinesin Inhibition, which this article extends by providing primary performance metrics and clarifying storage and solubility parameters.

Common Pitfalls or Misconceptions

• GSK-923295 does not inhibit other mitotic kinesins at concentrations effective for CENP-E inhibition; off-target effects are minimal within the recommended dose range (APExBIO).
• The compound is insoluble in water and must be dissolved in DMSO (≥29.6 mg/mL) or ethanol (≥14.87 mg/mL, ultrasonic assistance) for biological assays.
• It is not intended for diagnostic or therapeutic use in humans or animals; research use only (APExBIO).
• Solutions are prone to degradation; prepare fresh aliquots and store at -20°C (APExBIO).
• Mitotic arrest induced by GSK-923295 is reversible upon washout, but prolonged exposure may trigger apoptosis in sensitive cell lines (GSK-923295: A Small-Molecule CENP-E Inhibitor Transforming...).

Workflow Integration & Parameters

Formulation & Handling: GSK-923295 is supplied as a solid (MW 592.14) by APExBIO (product page). Solutions should be prepared in DMSO or ethanol using ultrasonic assistance for optimal solubility. Avoid repeated freeze-thaw cycles and store at -20°C.

Experimental Design: For cell-based assays, working concentrations typically range from 10–500 nM, with exposure times from 1 to 72 hours depending on assay endpoint. In vivo, dosing regimens such as 125 mg/kg i.p. have demonstrated efficacy in xenograft models.

Protocols and troubleshooting for cell cycle and cytotoxicity assays using GSK-923295 (SKU a3450) are detailed in GSK-923295 (SKU a3450): Reliable CENP-E Inhibition for Mitotic Studies; this article further specifies physicochemical parameters and highlights recent centromere biology insights.

Conclusion & Outlook

GSK-923295 is a validated, potent CENP-E inhibitor for dissecting mitotic checkpoint signaling and chromosome alignment pathways in cancer research. Its high specificity, robust in vitro and in vivo activity, and defined solubility/storage parameters make it an essential tool for advanced cell cycle and antitumor studies. Ongoing research into centromere maintenance and chromatin architecture, including the roles of CTCF and cohesin, will refine the mechanistic context for GSK-923295 and similar inhibitors. Future work may expand its utility in combination therapies or in studies of aneuploidy and chromosomal instability.